560P Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC

达布拉芬尼 医学 奥西默替尼 曲美替尼 癌症研究 突变体 肿瘤科 突变 靶向治疗 内科学 表皮生长因子受体 激酶 埃罗替尼 MAPK/ERK通路 基因 威罗菲尼 遗传学 癌症 黑色素瘤 生物 转移性黑色素瘤
作者
C. Weng,Kejing Tang,Shijie Jin,Chenfei Zhou,Yueliang Yao,J-W. Su,Huarong Chen,Kan Liu,Yuan Li,Jin‐Ji Yang
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1688-S1688
标识
DOI:10.1016/j.annonc.2023.10.638
摘要

This study represents, to our knowledge, the first cohort study investigation into the efficacy and safety of a triple-targeted therapy comprising EGFR/BRAF/MEK inhibitors dabrafenib, trametinib and osimertinib for NSCLC patients with acquired BRAF V600E mutation after EGFR-TKI treatment. Patient-derived organoid (PDO) experiments were conducted to further elucidate the drug response. A retrospective review of medical records was performed in multi-centers to analyze EGFR-mutant advanced NSCLC patients who developed acquired BRAF V600E mutation following EGFR-TKI treatment. All patients subsequently received dabrafenib, trametinib and osimertinib treatment. Clinical characteristics were documented, and progression-free survival (PFS) and adverse events (AEs) were assessed. In vivo drug response of PDOs were observed concurrently. Next-generation sequencing (NGS) was performed upon progression to triple-targeted therapy. Twelve patients with NGS-detected acquired BRAF V600E mutations were included in the study. Following triple-targeted therapy, the corresponding objective response rate (ORR) and disease control rate (DCR) was 58.3%, and 83.3%, respectively. The median PFS was 13.5 (95% CI: 9.8-17.2) months. No patients discontinued the treatment due to severe AEs. PDOs derived from one patient’s tumor sample were established, revealing that the triple-targeted therapy demonstrated a significantly lower IC50 value compared to other regimens. The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib plus osimertinib, 99.25% for osimertinib plus vemurafenib, 98.92% for osimertinib, encorafenib plus cetuximab, and 62.83% for pemetrexed plus carboplatin, respectively. NGS analysis identified major resistance mechanism following triple-targeted therapy, including EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and off-target mechanism. EGFR/BRAF/MEK triple-targeted therapy is an effective and safety approach for treating acquired BRAF V600E mutation in EGFR-mutant NSCLC patients resistant to EGFR-TKIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无情的幻嫣完成签到,获得积分10
刚刚
1秒前
李小小飞完成签到,获得积分10
2秒前
3秒前
hello完成签到,获得积分10
3秒前
我是老大应助无情的幻嫣采纳,获得10
3秒前
Roman完成签到,获得积分10
4秒前
slin_sjtu发布了新的文献求助10
6秒前
周周发布了新的文献求助20
6秒前
小党完成签到,获得积分10
6秒前
7秒前
昏睡的白桃完成签到,获得积分10
7秒前
小宇OvO发布了新的文献求助10
8秒前
jiaolulu发布了新的文献求助10
12秒前
量子星尘发布了新的文献求助10
12秒前
真的不想干活了完成签到,获得积分10
12秒前
美丽的依琴完成签到,获得积分10
13秒前
Xin完成签到,获得积分10
19秒前
Aurora.H完成签到,获得积分10
22秒前
22秒前
FashionBoy应助科研通管家采纳,获得10
23秒前
打打应助科研通管家采纳,获得10
23秒前
Jasper应助科研通管家采纳,获得10
23秒前
Ava应助科研通管家采纳,获得10
23秒前
顾矜应助科研通管家采纳,获得10
23秒前
上官若男应助科研通管家采纳,获得10
23秒前
duckspy发布了新的文献求助10
25秒前
25秒前
25秒前
xiaowan完成签到,获得积分10
26秒前
Terry完成签到,获得积分10
27秒前
张张张哈哈哈完成签到,获得积分10
27秒前
Research完成签到 ,获得积分10
27秒前
称心采枫完成签到 ,获得积分0
28秒前
28秒前
新新新新新发顶刊完成签到 ,获得积分10
29秒前
L3完成签到,获得积分10
30秒前
我是科研小能手完成签到,获得积分10
30秒前
风中的小丸子完成签到,获得积分10
31秒前
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022